The global demand for Biosimilars Market is presumed to reach the valuation of nearly USD XX MN by 2027 from USD XX MN in 2020 with a CAGR of XX% under the study period of 2020 - 2027.
A biosimilar is defined as a biologic medical product extremely similar to another already approved biological medication. Biosimilars are not generic drugs, but they are highly similar to originator biologic agents. The primary benefit of Biosimilars is less expensive as compared to the originators. Biosimilars are permitted as per the same standards of pharmaceutical quality, efficacy, and safety that are valid to all biological medicines. Biosimilars also have considerably higher research and development costs and risks and are more complicated to manufacture than small-molecule generics. Biosimilars have the prospective to give additional treatment options at a lesser price, but its development requires substantial investment.
The rising prevalence of chronic diseases and the high demand for biosimilars due to their cost-effectiveness are the primary factors driving the biosimilars market. The increasing collaborations for biosimilar research and clinical trials and strong product pipeline contribute to the biosimilars market's growth. The growing geriatric population and the patent expiry of biologic products are positively impacting the biosimilars market's growth. Moreover, the recent biosimilar product approvals in major countries and the rising number of product launches that will drive market growth is likely to create beneficial growth opportunities for key players of the biosimilars market in the coming years.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of biosimilars.
This section of the biosimilars market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Type of Manufacturing
- Recombinant human growth hormone (rhGH)
- Granulocyte colony-stimulating factor
- Monoclonal antibodies( Rituximab, Infliximab, Adalimumab, Trastuzumab and Other Monoclonal Antibodies)
- Enoxaparin Sodium
- In-House Manufacturing
- Contract Manufacturing
- Offsite Treatment
- Chronic Disorder
- Autoimmune Disease
- Blood Disorders
- Infectious Disease
- Other Diseases
This section covers regional segmentation which accentuates on current and future demand for Biosimilars market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Europe Biosimilars Market by Revenue (USD MN)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the biosimilars market include Zydus Cadila , Amgen, 3SBio, Biogen, Biocon, Boehringer Ingelheim, Coherus BioSciences, Elli Lilly and Company, , Celltrion, Intas Biopharmaceuticals, Lupin, Dr. Reddy's Laboratories, Merck, Novartis (Sandoz), Ratiopharm, Samsung Bioepis, Sanofi, STADA Arzneimittel, Teva Pharmaceutical, Wockhardt.S. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.